Get the Stockscreener App
4.59
21.54%
-1.26
After Hours:
4.64
0.05
+1.09%
Artelo Biosciences Inc stock is traded at $4.59, with a volume of 205.40K.
It is down -21.54% in the last 24 hours and down -50.38% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$5.85
Open:
$4.52
24h Volume:
205.40K
Relative Volume:
0.31
Market Cap:
$3.23M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-1.4525
EPS:
-3.16
Net Cash Flow:
$-8.96M
1W Performance:
-20.45%
1M Performance:
-50.38%
6M Performance:
-12.57%
1Y Performance:
-31.71%
1-Day Range:
$4.42
$4.8867
1-Week Range:
$4.42
$5.99
52-Week Range:
$4.20
$28.60
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
4.59 | 11.48M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Is Artelo Biosciences Inc. stock a top momentum playWeekly Earnings Recap & Weekly Breakout Opportunity Watchlist - newser.com
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering - GlobeNewswire
Artelo Biosciences prices $2 million public offering of common stock By Investing.com - Investing.com Australia
$2 Million Capital Raise: Artelo Biosciences Prices Public Offering for Cancer Drug Development - Stock Titan
Form 424B5 ARTELO BIOSCIENCES, INC. - StreetInsider
Candlestick signals on Artelo Biosciences Inc. stock todayWeekly Profit Summary & Daily Volume Surge Trade Alerts - newser.com
Why Wolfspeed Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket - Benzinga
Is Artelo Biosciences Inc. stock a defensive play in 20252025 Momentum Check & Consistent Profit Trading Strategies - newser.com
How Artelo Biosciences Inc. stock performs during Fed tightening cyclesQuarterly Trade Report & Community Verified Swing Trade Signals - newser.com
When is the best time to exit Artelo Biosciences Inc.Day Trade & Community Consensus Trade Alerts - newser.com
Artelo Biosciences launches underwritten public offering of stock - Investing.com India
Artelo Biosciences, Inc. Announces Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Artelo Biosciences Announces Proposed Underwritten Public Offering - GlobeNewswire
Nasdaq-Listed Biotech Artelo Biosciences Announces New Public Stock Offering for Cancer Research - Stock Titan
Can Artelo Biosciences Inc. stock surprise with earnings upsideWeekly Investment Summary & AI Powered Trade Plan Recommendations - newser.com
Statistical indicators supporting Artelo Biosciences Inc.’s strengthJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com
How to track smart money flows in Artelo Biosciences Inc.Weekly Profit Report & Fast Exit and Entry Strategy Plans - newser.com
Artelo Biosciences (ARTL) Shares Promising Interim Data from Pha - GuruFocus
Artelo Biosciences Announces Presentation of Positive - GlobeNewswire
Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference - MarketScreener
6% Weight Gain: Artelo's Cancer Cachexia Drug Shows Promising Results in Phase 2 Trial with Activity Boost - Stock Titan
Visual trend scoring systems applied to Artelo Biosciences Inc.Gold Moves & Free AI Powered Buy and Sell Recommendations - newser.com
Is Artelo Biosciences Inc. stock a safe haven assetEarnings Risk Summary & Growth Focused Stock Reports - newser.com
How to integrate Artelo Biosciences Inc. into portfolio analysis toolsTrade Performance Summary & Low Drawdown Investment Ideas - newser.com
Aug PreEarnings: What is Artelo Biosciences Incs TAM Total Addressable MarketQuarterly Profit Review & Verified Short-Term Plans - خودرو بانک
Can Artelo Biosciences Inc. continue delivering strong returnsPortfolio Risk Report & Verified High Yield Trade Plans - خودرو بانک
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):